4/A//SEC Filing
Gosebruch Henry O 4/A
Accession 0001179110-22-003107
CIK 0001551152other
Filed
May 19, 8:00 PM ET
Accepted
May 20, 5:00 PM ET
Size
13.4 KB
Accession
0001179110-22-003107
Insider Transaction Report
Form 4/AAmended
AbbVie Inc.ABBV
Gosebruch Henry O
Chief Strategy Officer
Transactions
- Sale
Common Stock, $0.01 par value
2022-03-01$146.81/sh−15,733$2,309,770→ 62,767 total(indirect: By Trust) - Sale
Common Stock, $0.01 par value
2022-03-01$147.60/sh−5,167$762,657→ 57,600 total(indirect: By Trust) - Sale
Common Stock, $0.01 par value
2022-03-01$148.71/sh−4,000$594,824→ 53,600 total(indirect: By Trust) - Sale
Common Stock, $0.01 par value
2022-03-01$149.38/sh−100$14,938→ 53,500 total(indirect: By Trust)
Holdings
- 41,623
Common Stock, $0.01 par value
- 3,457(indirect: By Trust)
Common Stock, $0.01 par value
Footnotes (7)
- [F1]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.31 to $147.30 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.35 to $148.11 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.37 to $148.96 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.38 to $149.39 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The reporting person is trustee of a trust established for the benefit of his children. The reporting person disclaims beneficial ownership of all securities held by the trust.
- [F6]Balance in AbbVie Savings program as of January 31, 2022.
- [F7]Due to an administrative error, the original Form 4 filed on March 2, 2022 incorrectly reported that the 25,000 securities sold on March 1, 2022 were securities directly owned by the reporting person. Instead, the securities sold on that date were securities indirectly owned in trust by the reporting person. This amended Form 4 corrects that error.
Documents
Issuer
AbbVie Inc.
CIK 0001551152
Entity typeother
Related Parties
1- filerCIK 0001659625
Filing Metadata
- Form type
- 4/A
- Filed
- May 19, 8:00 PM ET
- Accepted
- May 20, 5:00 PM ET
- Size
- 13.4 KB